Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics (Nasdaq: PSTV) has secured a significant national coverage agreement with UnitedHealthcare Insurance Company for its CNSide® Cerebrospinal Fluid Tumor Cell Enumeration test. The agreement, effective September 15, 2025, extends coverage to over 51 million people across the United States.
The CNSide® CSF Assay Platform, which has demonstrated 92% sensitivity and 95% specificity, aids in diagnosing and monitoring patients with leptomeningeal metastases. The test has been validated through 9 peer-reviewed publications and the FORESEE clinical trial, with over 11,000 tests performed at more than 120 U.S. cancer institutions since 2020, influencing treatment decisions in 90% of cases.
Plus Therapeutics (Nasdaq: PSTV) ha assicurato un significativo accordo di copertura nazionale con UnitedHealthcare Insurance Company per il suo test CNSide® Cerebrospinal Fluid Tumor Cell Enumeration. L'accordo, in vigore dal 15 settembre 2025, estende la copertura a oltre 51 milioni di persone negli Stati Uniti.
La CNSide® CSF Assay Platform, che ha dimostrato un'accuratezza del 92% e una specificità del 95%, aiuta nella diagnosi e nel monitoraggio dei pazienti con metastasi leptomeniniche. Il test è stato validato attraverso 9 pubblicazioni peer-reviewed e lo studio FORESEE, con oltre 11.000 test eseguiti in più di 120 istituti oncologici statunitensi dal 2020, influenzando le decisioni di trattamento nel 90% dei casi.
Plus Therapeutics (Nasdaq: PSTV) ha asegurado un importante acuerdo de cobertura nacional con UnitedHealthcare Insurance Company para su prueba CNSide® Enumeración de Células Tumorales en LCR. El acuerdo, vigente desde el 15 de septiembre de 2025, amplía la cobertura a más de 51 millones de personas en Estados Unidos.
La plataforma CNSide® CSF Assay, que ha mostrado una sensibilidad del 92% y una especificidad del 95%, ayuda a diagnosticar y hacer seguimiento a pacientes con metástasis leptomenínicas. La prueba ha sido validada a través de 9 publicaciones revisadas por pares y el ensayo FORESEE, con más de 11,000 pruebas realizadas en más de 120 instituciones oncológicas de EE. UU. desde 2020, influyendo en las decisiones de tratamiento en el 90% de los casos.
Plus Therapeutics (나스닥: PSTV)는 CNSide® 뇌척수액 종양 세포 계수 검사에 대해 UnitedHealthcare Insurance Company와 중요한 전국 커버리지 계약을 체결했습니다. 계약은 2025년 9월 15일 발효되며 미국 전역의 5100만 명 이상에게 커버리지를 확장합니다.
CNSide® CSF Assay Platform은 92% 민감도와 95% 특이도를 보여주며 뇌척수액 전이 환자의 진단 및 모니터링에 도움을 줍니다. 이 검사는 9편의 동료심사 저널에 실린 논문과 FORESEE 임상시험을 통해 검증되었으며, 2020년 이래 120개 이상의 미국 암 진단기관에서 11,000건 이상의 검사가 수행되었고, 사례의 90%의 치료 결정에 영향을 주었습니다.
Plus Therapeutics ( Nasdaq : PSTV) a sécurisé un accord majeur de couverture nationale avec UnitedHealthcare Insurance Company pour son test CNSide® Enumeration des cellules tumorales du LCR. L'accord, en vigueur à partir du 15 septembre 2025, étend la couverture à plus de 51 millions de personnes à travers les États-Unis.
La plateforme CNSide® CSF Assay Platform, qui a démontré une sensibilité de 92% et une spécificité de 95%, aide au diagnostic et au suivi des patients atteints de métastases leptomonéales. Le test a été validé par 9 publications évaluées par des pairs et l'essai FORESEE, avec plus de 11 000 tests effectués dans plus de 120 institutions oncologiques américaines depuis 2020, influençant les décisions de traitement dans 90% des cas.
Plus Therapeutics (Nasdaq: PSTV) hat eine bedeutende nationale Deckungsvereinbarung mit UnitedHealthcare Insurance Company für seinen CNSide® Cerebrospinal Fluid Tumor Cell Enumeration-Test gesichert. Die Vereinbarung, in Kraft ab dem 15. September 2025, erweitert die Deckung auf über 51 Millionen Menschen in den Vereinigten Staaten.
Die CNSide® CSF Assay Platform, die eine Sensitivität von 92% und Spezifität von 95% gezeigt hat, unterstützt die Diagnose und Überwachung von Patienten mit leptomeningealer Metastasierung. Der Test wurde durch 9 peer-reviewed Publikationen und die FORESEE-Studie validiert, mit über 11.000 Tests in mehr als 120 US-Krebseinrichtungen seit 2020 durchgeführt, und beeinflusst Entscheidungen zur Behandlung in 90% der Fälle.
أعلنت شركة Plus Therapeutics (مدرجة في ناسداك: PSTV) عن اتفاق واسع للتغطية الوطنية مع UnitedHealthcare Insurance Company لاختبار CNSide® Enumeration الخلوي لسائل النخاع الدماغي الورمي. يبدأ سريان الاتفاق في 15 سبتمبر 2025 ويغطي أكثر من 51 مليون شخص في الولايات المتحدة.
منصة CNSide® CSF Assay، التي أظهرت حساسية 92% وخصوصية 95%، تساعد في تشخيص ومراقبة المرضى المصابين بورم النخاع السائل الدماغي. تم التحقق من الاختبار من خلال 9 منشورات محكمة وتجربة FORESEE، مع إجراء أكثر من 11,000 اختبار في أكثر من 120 مؤسسة رعاية سرطان في الولايات المتحدة منذ 2020، وتأثيره في اتخاذ قرارات العلاج في 90% من الحالات.
Plus Therapeutics（纳斯达克股票代码：PSTV）已与 UnitedHealthcare Insurance Company 就其 CNSide® 脑脊液肿瘤细胞枚举测试达成重要的全国覆盖协议。该协议自 2025年9月15日 生效，将覆盖扩展至美 国超过 5100万名人。
CNSide® CSF Assay Platform，已显示出 92% 敏感性和 95% 特异性，有助于诊断和监测脑膜转移患者。该测试已通过 9 篇同行评审论文 和 FORESEE 临床试验验证，自 2020 年以来，在 120 家美国癌症机构执行超过 11,000 次测试，并在 90% 的病例中影响治疗决策。
- Secured national coverage agreement with UnitedHealthcare, reaching over 51 million people
- High clinical efficacy with 92% sensitivity and 95% specificity rates
- Strong market validation with 11,000+ tests performed across 120+ U.S. cancer institutions
- Test influences treatment decisions in 90% of cases
- Backed by 9 peer-reviewed publications and clinical trial data
- None.
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH), effective September 15, 2025, covering over 51 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT).
The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.
More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (
This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com.
About UnitedHealthcare Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
Investor Contact
CORE IR
investor@plustherapeutics.com
FAQ
What is the coverage agreement between Plus Therapeutics (PSTV) and UnitedHealthcare?
How effective is the CNSide® test for metastatic CNS cancer?
How many CNSide® tests has Plus Therapeutics performed since 2020?
What clinical validation supports Plus Therapeutics' CNSide® test?
When does the UnitedHealthcare coverage for PSTV's CNSide® test begin?
